DeLLphi-312: A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer

Condition: Small Cell Lung Cancer

Sponsor: Amgen

Full Title
Protocol 20240178: A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer

Study Treatment
Treatment on study is randomized 1:1 between the investigational arm of 4 cycles of Carboplatin, Etoposide, Durvalumab, and DLL3xCD3 targeting bispecific antibody Tarlatamab followed by Durvalumab and Tarlatamab maintenance therapy versus the control arm of 4 cycles of Carboplatin, Etoposide, and Durvalumab followed by Durvalumab maintenance therapy. 

Eligibility/Info
Eligible patients must have extensive stage small cell lung cancer that is suitable to receive carboplatin, etoposide, and durvalumab regimen as first-line treatment per investigator clinical assessment. 

Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage